Vasgen

Executive Summary

Vasgen Ltd is a UK-based preclinical biotechnology company founded in 2016, specializing in developing monoclonal antibody therapeutics for unmet needs in ophthalmology and oncology. The company leverages its proprietary AbIMP® platform to selectively inhibit challenging metzincin protease targets, particularly ADAM family sheddases. This approach aims to address diseases with high medical need, such as certain cancers and retinal conditions, by blocking key proteases involved in disease progression. Vasgen's technology has the potential to offer novel mechanisms of action compared to existing therapies. However, as a preclinical private company with no disclosed funding or revenue, the risk profile is high, and the path to clinical development remains uncertain. The scientific rationale and innovative platform provide a strong foundation for future value creation, contingent on successful preclinical validation and financing.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for Lead Candidate50% success
• Q4 2026Series A or Seed Funding Round40% success
• TBDPartnership or Licensing Deal with Larger Pharma30% success